



(51) International Patent Classification:

A61K 31/519 (2006.01) A61K 31/5386 (2006.01)
A61K 31/541 (2006.01) A61K 31/553 (2006.01)
A61K 31/517 (2006.01) A61P 35/00 (2006.01)
A61K 31/55 (2006.01)

(21) International Application Number:

PCT/US2024/052877

(22) International Filing Date:

24 October 2024 (24.10.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/593,212 25 October 2023 (25.10.2023) US
63/572,126 29 March 2024 (29.03.2024) US

(71) Applicant: KUMQUAT BIOSCIENCES INC. [US/US];
10770 Wateridge Circle, Suite 120, San Diego, California
92121 (US).

(72) Inventors: HANSEN, Rasmus; c/o 10770 Wateridge Cir-
cle, Suite 120, San Diego, California 92121 (US). JANES,
Matthew R.; c/o 10770 Wateridge Circle, Suite 120, San

Diego, California 92121 (US). LIU, Yi; c/o 10770 Wa-
teridge Circle, Suite 120, San Diego, California 92121 (US).

(74) Agent: MALECHA, James et al.; 650 Page Mill Road, Pa-
lo Alto, 94304 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,

(54) Title: METHODS OF MODULATING CELL PROLIFERATION

FIG. 1A

% growth inhibition

Compound-K (nM)	3125x-	70.79	74.04	74.02	75.6	73.81	75.96	76.41
	625x-	64.04	64.7	70.29	74.41	73.03	75.64	78.95
	125x-	60.5	65.8	69.17	71.81	71.7	68.37	76.09
	25x-	46.31	57.91	63.48	66.14	64.25	67.77	64.69
	5x-	17.57	20.69	29.6	51.24	54.71	54.77	58.04
	1x-	5.97	14.93	12.07	24.26	25.71	23.35	21.64
	0-	8.97	1.88	12.76	14.38	20.66	17.96	19.87
Conc (nM)	0	1x	5x	25x	125x	625x	3125x	
Compound-A (nM)								

(57) Abstract: The present disclosure provides compounds and pharmaceutically acceptable salts thereof. The present disclosure further provides methods of using the compounds and pharmaceutically acceptable salts thereof, for example in combinations of two or more compounds. The compounds and methods have a range of utilities as therapeutics, diagnostics, and research tools. In particular, the subject compositions and methods are useful for reducing signaling output of oncogenic proteins.

[Continued on next page]

SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*
- *with sequence listing part of description (Rule 5.2(a))*